Physician profile
Ghazanfar Abdullah
NPI 1639108137
$33,431.76
in general payments reported to CMS, 2019-2025
26 companies · $2,435 in 2025
The $2,435 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $1,385 · 2021: $2,689 · 2022: $3,957 · 2023: $4,111 · 2024: $3,777 · 2025: $2,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,324.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $11,934.82 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $9,026.29 | 2019-2025 | Yeztugo, Sunlenca, Epclusa |
| Janssen Biotech, INC. | $2,399.87 | 2019-2023 | Symtuza |
| Abbvie INC. | $1,991.74 | 2020-2025 | Mavyret, Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,878.12 | 2021-2025 | Relistor |
| Napo Pharmaceuticals INC | $1,376.48 | 2019 | |
| Janssen Products, LP | $1,329.64 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $678.86 | 2021-2025 | Pifeltro, Delstrigo, Isentress |
| Paratek Pharmaceuticals, INC. | $628.70 | 2024-2025 | Nuzyra |
| Forte Bio-Pharma LLC | $485.64 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Orexo US, INC. | $362.10 | 2022-2023 | Zubsolv |
| Lilly USA, LLC | $245.90 | 2019-2024 | Mounjaro |
| Mannkind Corporation | $231.98 | 2021 | |
| Madrigal Pharmaceuticals | $141.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Neurocrine Biosciences, INC. | $102.97 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $82.29 | 2020-2025 | Bexsero, Shingrix |
| Pfizer INC. | $81.69 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.32 | 2022-2023 | Jardiance, Synjardy |
| Nestle Healthcare Nutrition INC. | $71.63 | 2020-2021 | |
| Alkermes, INC. | $65.15 | 2019-2024 | Vivitrol |
| Janssen Pharmaceuticals, INC | $57.46 | 2020-2021 | |
| Lundbeck LLC | $42.92 | 2021-2023 | Rexulti |
| Althera Pharmaceuticals LLC | $41.51 | 2021-2022 | |
| Ibsa Pharma INC. | $39.06 | 2024 | Tirosint, Flector, Licart |
| Emd Serono, INC. | $38.20 | 2025 | |
| Indivior INC. | $19.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghazanfar Abdullah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.